Azacitidine in outpatient treatment - single center experience.

Rybka, Justyna; Stefanko, Ewa; Bogucka-Fedorczuk, Aleksandra; Butrym, Aleksandra; Poreba, Rafal; Kuliczkowski, Kazimierz; Wróbel, Tomasz

Rybka, Justyna; Stefanko, Ewa; Bogucka-Fedorczuk, Aleksandra; Butrym, Aleksandra; Poreba, Rafal; Kuliczkowski, Kazimierz; Wróbel, Tomasz.

Afiliação

Rybka J; Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland.
Stefanko E; Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland.
Bogucka-Fedorczuk A; Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland.
Butrym A; Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland; Department of Physiology, Wroclaw Medical University, Wroclaw, Poland.
Poreba R; Department of Internal Medicine, Wroclaw Medical University, Wroclaw, Poland.
Kuliczkowski K; Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland.
Wróbel T; Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland.

Contemp Oncol (Pozn) ; 19(6): 467-70, 2015.

Article em En | MEDLINE | ID: mdl-26843844

Palavras-chave

azacitidine; myelodysplastic syndrome; outpatient treatment

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Contemp Oncol (Pozn) Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Polônia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google